| Primary |
| Metastatic Malignant Melanoma |
45.0% |
| Malignant Melanoma |
42.5% |
| Pain |
1.7% |
| Nausea |
1.5% |
| Premedication |
1.2% |
| Malignant Melanoma Stage Iv |
1.0% |
| Hypertension |
0.9% |
| Metastases To Liver |
0.7% |
| Constipation |
0.6% |
| Metastatic Ocular Melanoma |
0.6% |
| Anxiety |
0.5% |
| Diabetes Mellitus |
0.5% |
| Atrial Fibrillation |
0.5% |
| Hypothyroidism |
0.5% |
| Metastases To Lung |
0.5% |
| Claustrophobia |
0.4% |
| Insomnia |
0.4% |
| Metastases To Central Nervous System |
0.4% |
| Ascites |
0.3% |
| Convulsion |
0.3% |
|
| Death |
22.7% |
| Diarrhoea |
10.1% |
| Neoplasm Malignant |
9.0% |
| Malignant Neoplasm Progression |
8.9% |
| Rash |
7.7% |
| Colitis |
5.8% |
| Adverse Event |
4.1% |
| Vomiting |
3.5% |
| Pruritus |
3.2% |
| Fatigue |
2.9% |
| Weight Decreased |
2.7% |
| Metastases To Central Nervous System |
2.6% |
| Enterocolitis |
2.3% |
| Nausea |
2.3% |
| Pyrexia |
2.3% |
| Hypophysitis |
2.1% |
| Infusion Related Reaction |
2.0% |
| Neuropathy Peripheral |
2.0% |
| Intestinal Perforation |
1.9% |
| Malaise |
1.9% |
|
| Secondary |
| Malignant Melanoma |
25.8% |
| Metastatic Malignant Melanoma |
16.1% |
| Product Used For Unknown Indication |
14.0% |
| Metastases To Liver |
11.8% |
| Metastases To Lung |
10.8% |
| Renal Cancer |
6.5% |
| Metastases To Central Nervous System |
4.3% |
| Lung Neoplasm |
2.2% |
| Nausea |
2.2% |
| Choroid Melanoma |
1.1% |
| Granulomatosis With Polyangiitis |
1.1% |
| Metastatic Neoplasm |
1.1% |
| Pain |
1.1% |
| Pituitary Enlargement |
1.1% |
| Prophylaxis |
1.1% |
|
| Respiratory Failure |
13.3% |
| Malignant Neoplasm Progression |
10.0% |
| Incorrect Storage Of Drug |
6.7% |
| Mental Status Changes |
6.7% |
| Off Label Use |
6.7% |
| Rash |
6.7% |
| Vomiting |
6.7% |
| Cellulitis |
3.3% |
| Constipation |
3.3% |
| Dehydration |
3.3% |
| Diarrhoea |
3.3% |
| Dyspnoea |
3.3% |
| Epilepsy |
3.3% |
| Fatigue |
3.3% |
| Hiatus Hernia |
3.3% |
| Hyponatraemia |
3.3% |
| Incorrect Product Storage |
3.3% |
| Metastasis |
3.3% |
| Muscular Weakness |
3.3% |
| Myocardial Infarction |
3.3% |
|
| Concomitant |
| Malignant Melanoma |
75.0% |
| Product Used For Unknown Indication |
25.0% |
|
| Metastases To Central Nervous System |
33.3% |
| Pyrexia |
33.3% |
| Urticaria |
33.3% |
|
